AEZS

Aeterna Zentaris Inc
3.63
-0.09 (-2.42%)

Aeterna Zentaris Inc. (AEZS) Fundamentals

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.
SHARE INFORMATION
Market Cap$ 18,063,859
Shares Outstanding121,397,007
Float4,851,119
Percent Float99.9%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 5,260,000
Latest Fiscal EPS$ -1.87
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions33
Institutional Holdings Date2023-01-31
Institutional Bought Previous 3 Months1,996
Institutional Holdings Percent0.7%
Institutional Sold Previous 3 Months3
Insider Holdings Date-
Insider Bought Previous 3 Months-
Insider Holdings Percent0.0
Insider Sold Previous 3 Months-
Insider Shares Owned3,595,318
TRADING INFO
52 Week High$ 10.99
52 Week Low$ 2.89
52 Week High Change$ -58.62
21 Day Moving Average$ 3.7043
21 Day Extended Moving Average$ 3.6958
50 Day Moving Average$ 3.6028
50 Day Extended Moving Average$ 3.6825
200 Day Moving Average$ 4.5641
200 Day Extended Moving Average$ 5.2339
10 Day Average Volume12,511
20 Day Average Volume12,786
30 Day Average Volume15,955
50 Day Average Volume16,700
Alpha-0.024638
Beta1.4297
Standard Deviation0.251154
R20.094535
7 Day Price Change$ 0.03
7 Day Percent Change0.81%
21 Day Price Change$ 0.06
21 Day Percent Change1.64%
30 Day Price Change$ 0.54
30 Day Percent Change16.98%
Month to Date Price Change$ -0.11
Month to Date Percent Change-2.87%
Quarter to Date Price Change$ 0.54
Quarter to Date Percent Change16.98%
180 Day Price Change$ -0.87
180 Day Percent Change-18.95%
200 Day Price Change$ -2.23
200 Day Percent Change-37.45%
Year to Date Price Change$ 0.54
Year to Date Percent Change16.98%

Aeterna Zentaris Inc. (AEZS) Key Ratios

PROFITABILITY
EBIT Margin-344.6%
EBITDA Margin-341.1%
Pre-Tax Profit Margin-289.4%
Profit Margin Count0.0%
Gross Margin97.0%
Profit Margin TOT0.0%
INCOME STATEMENTS
Revenue$ 3,155,000
Revenue Per Share$ 0.6497
Revenue (3 Years)$ 88.32
Revenue (5 Years)$ 15.11
FINANCIAL STRENGTH
Price to Tangible Book0.40
Total Debt To Equity0.00
Int Coverage191,002.20
Current Ratio9.80
Leverage Ratio1.40
Quick Ratio9.40
Long Term Debt To Capital0.00
VALUATION MEASURES
PE Ratio-1.50
Enterprise Value$ -35,377,473
Price to Sales5.7255
Price to Free Cash-1.70
PE High Last 5 Years21.90
Price To Book0.40
Price To Cash Flow9.90
PE Low Last 5 Years-2.90
Price to Tangible Book0.40
MANAGEMENT EFFECTIVENESS
Receivables Turnover0.70
Invoice Turnover0.80
Assets Turnover0.00
Return Assets-17.72
Return on Equity-24.09
Return on Capital-24.03

Aeterna Zentaris Inc. (AEZS) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
AuditorErnst & Young LLP
CEOKlaus Paulini
Emplyoees17
Last AuditUQ
CIK0001113423
IndustryBiotechnology
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
Addressc/o Norton Rose Fulbright Canada, LLP
222 Bay Street
Toronto, ON M5K 1E7
Websitehttps://www.zentaris.com
Facsimile-
Telephone+1 843 900-3223
EmailIR@aezsinc.com


Your Recent History
NASDAQ
AEZS
Aeterna Ze..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.